AllayPay launches U.S. processing program for RUO peptide merchants

AllayPay has expanded its merchant services offering for research-use-only peptide sellers, giving qualified businesses a domestic U.S. processing option with faster approvals, multiple payment methods and direct underwriting support. The move targets a category that has often been shut out of mainstream payments because of compliance risk and chargeback exposure.

Why it matters: - Research use only peptide merchants have often faced rejections from mainstream processors because of regulatory and compliance risk. - Many sellers that do secure processing are pushed to offshore setups with slower funding, higher reserves, unexpected holds and account shutdown risk. - AllayPay is positioning a domestic option for a niche market that has grown alongside demand for GLP-1 and semaglutide-related compounds.

What happened: - AllayPay, a U.S.-based merchant services provider focused on high-risk industries, announced an expanded processing program for qualified RUO peptide merchants. - The program is built for research-use-only manufacturers, online retailers and other eligible research-focused sellers. - Qualified merchants can use a fully domestic U.S. merchant account for credit card processing without routing transactions offshore. - The announcement was made Sept. 30, 2026, from Plantation, Florida.

The details: - AllayPay serves as the direct ISO for RUO peptide processing and works with banking partners to handle underwriting and account approval. - Credit card approvals average 1 to 2 business days, and ACH approvals take 2 to 3 business days. - The program offers a 97%+ authorization approval rate and standard 1- to 2-day funding. - Merchants can process credit cards, ACH and eCheck payments under one account. - Supported shopping cart integrations include WooCommerce, Shopify, BigCommerce, Magento and Ecwid. - Startups are eligible if they provide proper upfront reserves. - AllayPay says the program covers manufacturers, suppliers, online retailers and companies offering peptide pharmaceuticals. - The program also supports businesses working with amino acids, GLP-1 compounds, semaglutides and retatrutides, plus eligible health providers offering peptide therapies. - The company is a registered ISO/MSP of Fifth Third Bank and says it maintains relationships with more than 30 acquiring banks. - More information is available at the company's website.

Between the lines: - The launch reflects a gap in payments infrastructure for a category that generic processors often avoid. - Faster approvals and domestic processing may matter most to merchants that have struggled with offshore funding delays and account instability. - The program is narrower than a general-purpose merchant account and is designed for genuine research-use sellers, not clinics, med spas or weight-loss providers. - The compliance bar remains high, which suggests AllayPay is trying to balance access with tighter underwriting discipline.

What's next: - Qualified merchants can apply online or contact AllayPay directly for quotes and onboarding. - Underwriting typically requires a 5% to 10% rolling or upfront reserve, depending on volume and processing history. - Required documentation includes government ID, a voided check or bank letter, and proof of a fulfillment agreement or owned inventory. - Merchant websites must meet RUO-specific standards, including age verification, a published lab report for each product, account-only checkout and scientific-only naming with no references to branded drugs like Ozempic or Wegovy.